Literature DB >> 19050801

E-cadherin expression in invasive breast cancer.

C Suciu1, Anca Maria Cîmpean, Anca Maria Mureşan, D Izvernariu, M Raica.   

Abstract

There were investigated 22 cases with invasive breast carcinoma from the archive material, and the immunohistochemical expression of E-cadherin was correlated with clinical stage, pathological type, grade of the tumor, and lymph nodes status. The expression of E-cadherin was assessed by the pattern of the final product of reaction and number of positive cells. The reaction was appreciated as normal if over 70% of tumor cells showed membrane of membrane and cytoplasmic pattern, and aberrant, if less than 70% of tumor cells were positive. There were found 45.5% cases with normal expression and 54.5% with aberrant expression. Strong positive reaction was found mainly in tumor cells invading the adipose tissue, but the reaction was weak or negative in tumor cells within the vessels. Both normal and aberrant expression of E-cadherin correlates with grade and with clinical stage. In our study was found that the increase of the tumor grade is associated with decrease in the expression of E-cadherin. Tumors over 2 cm in their larger diameter showed a decreased expression of E-cadherin. Seventeen from 22 cases with lymph node metastasis had positive reaction in the primary, but there were not found significant differences between the normal and aberrant expression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19050801

Source DB:  PubMed          Journal:  Rom J Morphol Embryol        ISSN: 1220-0522            Impact factor:   1.033


  1 in total

1.  Epithelial-Cadherin Expression Is Associated With Better Recurrence-Free and Overall Survival in Invasive Lobular Breast Cancer in Mexican Women.

Authors:  Ricardo Fernandez-Ferreira; Rita Dorantes-Heredia; Daniel Motola-Kuba; Jose-Manuel Ruiz-Morales; Gabriela Alvarado-Luna; Ileana Mac Kinney-Novelo; Wendy-Rossemary Munoz-Montano; Kevin-Joseph Fuentes-Calvo
Journal:  World J Oncol       Date:  2021-12-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.